Phoreus Biotech develops Branched Amphipathic Peptide Capsules (BAPC®️) and Corralling Amphipathic Peptide Colloids (CAPC™️) for the precise delivery of genetic vaccines and therapeutics, enhancing stability and efficacy while eliminating the need for cold chain storage. Their technology addresses the challenge of vaccine accessibility by ensuring that sensitive nucleic acid components remain stable at room temperature, thereby facilitating broader distribution and use.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic vaccines and therapeutics require cold chain storage, which limits their accessibility and increases distribution costs, especially in resource-limited settings. Existing nanocarriers may also lack the necessary stability, biocompatibility, or biodegradability for effective drug delivery.
Solution
Phoreus Biotech offers two proprietary technology platforms, Branched Amphipathic Peptide Capsules (BAPC®️) and Corralling Amphipathic Peptide Colloids™️ (CAPC™️), designed for precision delivery of genetic vaccines and therapeutics. These self-assembling, peptide-based nanoparticles enhance the stability and efficacy of nucleic acid payloads, potentially eliminating the need for cold chain storage. The nanocarriers are engineered to be non-toxic to cells and biodegradable, facilitating a simple transition from in-vitro research to in-vivo applications. Phoreus' technology improves drug absorption and delivery, leading to superior results in human, animal, plant, and environmental health applications.
Target Audience
The primary target audience includes researchers and companies in the fields of medical vaccines and therapeutics, veterinary medicine, plant science, and biopesticides seeking improved drug delivery systems.
Features
- Branched Amphipathic Peptide Capsules (BAPC®️): Solvent-filled, bilayer-defined capsules formed from self-assembling branched peptides.
- Corralling Amphipathic Peptide Colloids™️ (CAPC™️): Alternative nanocarrier platform for specific drug delivery needs.
- Enhanced thermostability: Allows mRNA and other sensitive components to remain stable at room temperature.
- Customizable BAPC®️: Nanocarriers can be tailored to specific research and application requirements.
- BAPtofect®️-25 kits: Pre-formulated 25 nm BAPC®️ for cell transfection research, optimized for maximum transfection rates.
- Non-immunogenic and minimally toxic: Designed for safe and effective delivery with minimal adverse effects.
- Biodegradable: Peptide-based carriers break down in biological systems without accumulating in the environment.